Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $200.00 Price Target at Barclays

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective decreased by Barclays from $230.00 to $200.00 in a research note released on Friday, Benzinga reports. Barclays currently has an overweight rating on the specialty pharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an overweight rating in a research note on Friday, March 22nd. Needham & Company LLC restated a buy rating and issued a $222.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday. Truist Financial reaffirmed a buy rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Stifel Nicolaus boosted their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a buy rating in a research report on Friday, March 15th. Finally, HC Wainwright lowered their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a buy rating for the company in a report on Thursday, March 14th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $192.75.

Jazz Pharmaceuticals Trading Down 0.1 %

NASDAQ:JAZZ traded down $0.16 during midday trading on Friday, reaching $109.85. 571,215 shares of the stock traded hands, compared to its average volume of 614,775. The stock has a market capitalization of $6.92 billion, a P/E ratio of 22.68, a PEG ratio of 1.53 and a beta of 0.63. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The company has a fifty day moving average of $116.44 and a 200 day moving average of $120.94. Jazz Pharmaceuticals has a 12 month low of $103.01 and a 12 month high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. On average, research analysts predict that Jazz Pharmaceuticals will post 16.24 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Philip L. Johnson bought 12,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 1st. The stock was acquired at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Insiders own 4.40% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in JAZZ. SG Americas Securities LLC purchased a new position in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $611,000. Asset Management One Co. Ltd. grew its position in Jazz Pharmaceuticals by 12.0% in the 3rd quarter. Asset Management One Co. Ltd. now owns 28,124 shares of the specialty pharmaceutical company’s stock worth $3,640,000 after purchasing an additional 3,004 shares during the period. Commonwealth Equity Services LLC raised its stake in Jazz Pharmaceuticals by 10.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company’s stock valued at $1,304,000 after buying an additional 962 shares during the last quarter. Pinnacle Associates Ltd. lifted its holdings in shares of Jazz Pharmaceuticals by 2.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 10,587 shares of the specialty pharmaceutical company’s stock valued at $1,370,000 after buying an additional 238 shares during the period. Finally, Forsta AP Fonden lifted its holdings in shares of Jazz Pharmaceuticals by 15.2% during the 3rd quarter. Forsta AP Fonden now owns 22,000 shares of the specialty pharmaceutical company’s stock valued at $2,848,000 after buying an additional 2,900 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.